Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 and JS213 in Advanced Malignant Solid Tumors
NCT07480733Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of JS212, JS213 in solid tumor, renal cell carcinoma (RCC), prostate cancer (PCa), urothelial carcinoma (UC), melanoma, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2026; status: recruiting.
02
Drugs
JS212JS213
03
Conditions
solid tumorrenal cell carcinoma (RCC)prostate cancer (PCa)urothelial carcinoma (UC)melanoma
Beyond the preview
Go deeper on NCT07480733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480733.